# Junta clínica — PT-pseudo_c13fda040310 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_c13fda040310",
  "pid": "PT-pseudo_c13fda040310",
  "task": 1,
  "psa": 6.1,
  "age": 63,
  "months": 3,
  "pirads": "4",
  "psad": 0.08,
  "psav": 1.35,
  "psap": 4.9,
  "vol": 73.0,
  "dre": "Normal",
  "bx": "Negative",
  "cspca": 0.81674135,
  "medhx": "Type 2 diabetes, Hypercholesterolaemia, Osteoarthritis, Benign prostatic hyperplasia",
  "meds": "metformin, empagliflozin, atorvastatin, simvastatin, rosuvastatin, paracetamol PRN, tamsulosin",
  "notes": "PSA 6.1 ng/mL. PI-RADS 4. PSAD 0.08. Prostate volume 73 mL. csPCa 0.82.",
  "pmhx": [
    "Type 2 diabetes",
    "Hypercholesterolaemia",
    "Osteoarthritis",
    "Benign prostatic hyperplasia"
  ],
  "allergies": [],
  "vitals": {
    "weight": "81 kg",
    "height": "180 cm",
    "bmi": "25.0",
    "bp": "125/95 mmHg",
    "hr": "72 bpm",
    "smoking": "Current smoker (23 pack-yr)",
    "last_dental": "6 mo ago",
    "flu_vax": "Oct 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "19 Feb 2025",
  "enc_ref": "Dr. E. Mulder (GP)",
  "enc_type": "Re-evaluation - prior negative biopsy",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "An escalating PSA trajectory reaching 6.1 ng/mL after a previously negative systematic biopsy necessitates specialist re-evaluation."
    },
    {
      "s": "History",
      "t": "Divorced and currently residing with a partner, the 63-year-old freelance translator entered initial prostate cancer risk assessment in mid-2023 following a PSA reading of 3.5 ng/mL. Over the subsequent two years, he has experienced a steady, asymptomatic PSA increase now reaching 6.1 ng/mL. Despite the earlier negative biopsy, he expresses considerable apprehension regarding another invasive procedure. Lower urinary tract symptoms remain minimal (IPSS 5), adequately controlled with tamsulosin and a routine of commuter cycling five times each week. His clinical background includes benign prostatic hyperplasia, well-managed type 2 diabetes treated with metformin and empagliflozin, as well as hypercholesterolaemia addressed through atorvastatin, simvastatin, and rosuvastatin. He maintains an active lifestyle despite being a current smoker with a 23 pack-year history. He explicitly denies haematuria, pelvic pain, or unexplained weight loss. A stable, decades-long right knee osteoarthritis restricts his marathon goals and occasionally requires paracetamol PRN. Weekly alcohol intake averages one unit, and he notes that extended hours spent translating technical documents frequently contribute to his general fatigue."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: smooth and firm; mobility: unrestricted; asymmetry: none. The prostate is symmetrically enlarged but otherwise unremarkable, confirming a normal digital rectal examination. General physical assessment shows no abnormalities, with clear cardiovascular and respiratory auscultation, absent peripheral lymphadenopathy, and no palpable abdominal masses."
    }
  ],
  "occupation": "freelance translator",
  "marital": "Divorced",
  "living": "Lives with partner",
  "next_of_kin": "Adult daughter (primary contact)",
  "recent_other": [],
  "alcohol": "1 units / week",
  "exercise": "Cycling 5x/week (commuter)",
  "ipss": "IPSS score: 5/35 (mild LUTS)",
  "admin": "Patient anxious about procedures — allocate extra consult time.",
  "mri_hospital": "Catharina Ziekenhuis (Eindhoven)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_c13fda040310
Task: 1

Encounter: Urology - outpatient on 19 Feb 2025.
Referrer: Dr. E. Mulder (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 63-year-old male
  - PSA: 6.1 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.08 ng/mL²
  - PSA velocity: 1.35 ng/mL/yr
  - Prior PSA: 4.9 ng/mL
  - Prostate volume: 73.0 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.81674135 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Type 2 diabetes, Hypercholesterolaemia, Osteoarthritis, Benign prostatic hyperplasia
  - Problem list / PMHx: Type 2 diabetes, Hypercholesterolaemia, Osteoarthritis, Benign prostatic hyperplasia
  - Current medication: metformin, empagliflozin, atorvastatin, simvastatin, rosuvastatin, paracetamol PRN, tamsulosin
  - Allergies: NKA
  - Additional notes: PSA 6.1 ng/mL. PI-RADS 4. PSAD 0.08. Prostate volume 73 mL. csPCa 0.82.

Vitals: weight 81 kg, height 180 cm, BMI 25.0, BP 125/95 mmHg, HR 72 bpm. Smoking: Current smoker (23 pack-yr).

Chief complaint: An escalating PSA trajectory reaching 6.1 ng/mL after a previously negative systematic biopsy necessitates specialist re-evaluation.

History: Divorced and currently residing with a partner, the 63-year-old freelance translator entered initial prostate cancer risk assessment in mid-2023 following a PSA reading of 3.5 ng/mL. Over the subsequent two years, he has experienced a steady, asymptomatic PSA increase now reaching 6.1 ng/mL. Despite the earlier negative biopsy, he expresses considerable apprehension regarding another invasive procedure. Lower urinary tract symptoms remain minimal (IPSS 5), adequately controlled with tamsulosin and a routine of commuter cycling five times each week. His clinical background includes benign prostatic hyperplasia, well-managed type 2 diabetes treated with metformin and empagliflozin, as well as hypercholesterolaemia addressed through atorvastatin, simvastatin, and rosuvastatin. He maintains an active lifestyle despite being a current smoker with a 23 pack-year history. He explicitly denies haematuria, pelvic pain, or unexplained weight loss. A stable, decades-long right knee osteoarthritis restricts his marathon goals and occasionally requires paracetamol PRN. Weekly alcohol intake averages one unit, and he notes that extended hours spent translating technical documents frequently contribute to his general fatigue.

Physical examination: DRE — texture: smooth and firm; mobility: unrestricted; asymmetry: none. The prostate is symmetrically enlarged but otherwise unremarkable, confirming a normal digital rectal examination. General physical assessment shows no abnormalities, with clear cardiovascular and respiratory auscultation, absent peripheral lymphadenopathy, and no palpable abdominal masses.

Patient info: freelance translator; Divorced; Lives with partner.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 1 units / week; exercise Cycling 5x/week (commuter); IPSS score: 5/35 (mild LUTS).


Admin: Patient anxious about procedures — allocate extra consult time.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-CLASSIFIER

*statistical classifier; suggests a starting point, decides nothing* · vuelta 1

A classifier trained only to open the discussion, not to close it. Here is its bid.

SUGGESTION: BIOPSY   p(biopsy) = 0.72
  uncertainty  +/- 0.13 (95% CI 0.46-0.98); among patients it cannot tell apart the outcome was 0.86 of 1.00 mixed
  confidence   MODERATE — in this tier it was right 80% of the time over 20 labelled cases

It read ONLY these variables: PI-RADS, prior biopsy status, PSA, age, PSA density, DRE, prostate volume, number of problems on the list. Nothing else — not the mpMRI prose, not the PSA
trajectory, not the previous notes, not this patient's management plan. Values it could not
read for this patient: none.
Out-of-fold over 91 labelled cases (5x5 StratifiedKFold, out-of-fold): accuracy 0.714 against a
majority-class baseline of 0.615, AUC 0.789, F1(yes) 0.78.

The final call is the senior urologist's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior negative biopsy. My criterion answers BIOPSY.

The criterion: repeat, targeted, when the mpMRI shows a PI-RADS 4-5 lesion; do not repeat a negative biopsy for an unchanged PI-RADS 3 or lower picture. In the labelled series this criterion matched the reading urologist in 16 of 18 cases in exactly this situation.

Like the classifier, I have read ONLY the visible panel — not the mpMRI prose, the PSA
trajectory, the previous notes or the laboratory panel. Departing from me needs a specific
finding from a document somebody actually opened, named out loud. Not a restatement of the
panel numbers I already used.

## Intervención 5 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines suggest that the decision to repeat biopsy depends on the MRI findings and other risk factors. The guideline states, "sion on MRI mandates a repeat biopsy to confirm histological progression before a change in treatment strategy." It also notes that factors like low PSA density and PSA velocity can be used to individualise the need for biopsy.

WHAT THE CLASSIFIER'S BID DOES NOT SETTLE
The classifier's suggestion of biopsy is not sufficiently grounded in the guideline because it ignores the specific risk stratification thresholds provided by the guideline. It fails to account for the guideline's emphasis on using variables like PSA density and PSA velocity to individualise the need for biopsy, which are critical for risk-adapted decision-making.

WHAT WE STILL NEED
The mpMRI prose - The mpMRI prose does not compare against an earlier study, so the guideline does not mandate a specific action based on this point.
PSA velocity - The guideline makes decisions based on PSA velocity, and the patient's value is 1.35 ng/mL/yr, which must be assessed against guideline thresholds.
PSA density - The guideline makes decisions based on PSA density, and the patient's value is 0.08 ng/mL², which must be assessed against guideline thresholds.
The mpMRI prose - The mpMRI prose does not compare against an earlier study, so the guideline does not mandate a specific action based on this point.

## Intervención 6 — MODERATOR

*chairs the discussion; sets the verification plan and the open questions* · vuelta 1

This case hinges on assessing the specific thresholds for PSA velocity and density as per the EAU guidelines, and reviewing the mpMRI prose to see if it mandates a repeat biopsy.

Before anyone argues, this is what I want established, and by whom.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  psa_trend (get_psa_trend) -> Determine the specific PSA velocity threshold mentioned in the EAU guidelines and compare it to the patient's value of 1.35 ng/mL/yr.
  radiology_report (get_mri_report) -> Determine if the mpMRI prose compares the current findings against an earlier study.

OPEN QUESTIONS for this conference — these are what the decision hangs on, and I expect them answered by name, not in general terms:
  Q1. What are the specific EAU guideline thresholds for PSA velocity and PSA density that should be applied to this patient's values?
  Q2. What does the mpMRI prose state regarding comparison against an earlier study?

On the plan itself: laboratory_results dropped: requested without naming one of the three questions that justify it (free-PSA fraction, infection or prostatitis explaining the PSA, fitness for the procedure). The DRE and the headline PSA are already on the panel.

## Intervención 7 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
psa_trend
The patient's PSA velocity is 1.35 ng/mL/yr.
radiology_report
The mpMRI prose does not compare the current findings against an earlier study.

WHAT I DID NOT OPEN
laboratory_results, because the moderator did not ask for them to justify the request.

WHAT THIS SUPPORTS
FOR sampling this patient now
The EXPERT-COHORT matched the urologist in 16 of 18 cases in this exact situation.
The EXPERT-CLASSIFIER suggested biopsy with a probability of 0.72.
AGAINST sampling this patient now
The EXPERT-EAU noted that the mpMRI prose does not compare against an earlier study, so the guideline does not mandate a specific action based on this point.

WHERE THIS LEANS
The data suggests a leaning towards biopsy based on the cohort matching, but the lack of comparison in the MRI prose leaves the decision unresolved.
LEAN: biopsy

## Intervención 8 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The registrar has answered the moderator's questions by providing the PSA velocity (1.35 ng/mL/yr) and confirming that the mpMRI prose does not compare findings against an earlier study.

ALIGNMENT WITH THE CLASSIFIER
The retrieved evidence does not directly align with the EXPERT-CLASSIFIER's suggestion of biopsy, as the EAU expert noted that the lack of comparison in the MRI prose means the guideline does not mandate action.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What are the specific EAU guideline thresholds for PSA velocity and PSA density that should be applied to this patient's values? Not answered; the registrar reported the value but did not state the thresholds.
Q2. What does the mpMRI prose state regarding comparison against an earlier study? Answered; the registrar stated that the mpMRI prose does not compare the current findings against an earlier study.

WHAT CARRIES WEIGHT, AND WHY
The two most relevant variables are PSA velocity, because the EAU guideline uses it to individualise the need for biopsy, and the mpMRI prose comparison status, because the EAU guideline explicitly states that a comparison is needed to mandate a repeat biopsy. The guideline does not support the leaning towards biopsy because the lack of comparison in the MRI prose leaves the decision unresolved.

MY SUGGESTION TO THE CHAIR
I suggest deferring the decision until the mpMRI prose is reviewed to see if it contains any comparative language that would satisfy the EAU guideline requirement for mandating a repeat biopsy.

VERDICT: not-ready | SUGGEST: defer | MISSING: radiology_report

[The conference reopens for pass 2: previous_notes still closed.]

## Intervención 9 — MODERATOR

*chairs the discussion; sets the verification plan and the open questions* · vuelta 2

We still need to review the previous notes to understand the prior management plan and the laboratory results to fully assess the risk factors.

We are reopening (pass 2). This is what the verifier says is still missing, and how I want it closed.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  previous_notes (get_previous_notes) -> Determine the management context, including prior biopsy results and surveillance plans.

OPEN QUESTIONS for this conference — these are what the decision hangs on, and I expect them answered by name, not in general terms:
  Q1. What does the previous notes state regarding the prior biopsy and surveillance protocol?
  Q2. What are the laboratory results, specifically regarding the PSA fraction, infection, or prostatitis, to contextualize the PSA value?

On the plan itself: Reveal budget is 1 more document(s) in this session; deferred laboratory_results. Every extra reveal is scored on precision.

## Intervención 10 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 2

WHAT I FOUND
previous_notes
The previous notes state that a systematic transrectal ultrasound-guided biopsy was carried out in June 2024, and the histological analysis returned entirely benign, with no signs of malignancy.

WHAT I DID NOT OPEN
laboratory_results, because the moderator did not ask for them to justify the request.

WHAT THIS SUPPORTS
FOR sampling this patient now
The EXPERT-COHORT matched the urologist in 16 of 18 cases in this exact situation.
The EXPERT-CLASSIFIER suggested biopsy with a probability of 0.72.
AGAINST sampling this patient now
The EXPERT-EAU noted that the mpMRI prose does not compare against an earlier study, so the guideline does not mandate a specific action based on this point.

WHERE THIS LEANS
The data suggests a leaning towards biopsy based on the cohort matching, but the lack of comparison in the MRI prose leaves the decision unresolved.
LEAN: biopsy

## Intervención 11 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 2

SUFFICIENCY
The registrar has answered Q1 by stating that a systematic transrectal ultrasound-guided biopsy was performed in June 2024 with entirely benign histological analysis, and has not answered Q2 as the laboratory results remain closed.

ALIGNMENT WITH THE CLASSIFIER
The retrieved evidence aligns with the EXPERT-CLASSIFIER's suggestion of biopsy because the cohort matching and classifier suggestion lean towards biopsy, which is supported by the finding that a prior biopsy was negative.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What does the previous notes state regarding the prior biopsy and surveillance protocol? Answered by the registrar, who stated that a systematic transrectal ultrasound-guided biopsy was carried out in June 2024 and the analysis returned entirely benign.
Q2. What are the laboratory results, specifically regarding the PSA fraction, infection, or prostatitis, to contextualize the PSA value? Not answered, as the laboratory results remain closed.

WHAT CARRIES WEIGHT, AND WHY
The two most relevant variables are the prior biopsy result, because the negative result is a key factor in the decision pathway, and the laboratory results, because the guideline requires context regarding PSA fraction, infection, or prostatitis to individualize the need for biopsy. The guideline does not support the leaning towards biopsy because the lack of information on the specific laboratory context leaves the decision unresolved.

MY SUGGESTION TO THE CHAIR
I suggest deferring the decision until the laboratory results are reviewed to determine if they provide the necessary context regarding PSA fraction, infection, or prostatitis, as this is a required element for risk-adapted decision-making.

VERDICT: not-ready | SUGGEST: defer | MISSING: laboratory_results

[The conference reopens for pass 3: 'laboratory_results' is named as missing and is still closed.]

## Intervención 12 — MODERATOR

*chairs the discussion; sets the verification plan and the open questions* · vuelta 3

We still need the laboratory results to contextualize the PSA value according to the EAU guidelines before we can make a final determination.

We are reopening (pass 3). This is what the verifier says is still missing, and how I want it closed.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  laboratory_results (get_lab_results) -> Determine the PSA fraction, infection, or prostatitis to contextualize the PSA value.

OPEN QUESTIONS for this conference — these are what the decision hangs on, and I expect them answered by name, not in general terms:
  Q1. What are the laboratory results, specifically regarding the PSA fraction, infection, or prostatitis, to contextualize the PSA value?

## Intervención 13 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 3

WHAT I FOUND
laboratory_results
The PSA fraction is "21%" on "04 Feb 2025".

WHAT I DID NOT OPEN
nothing

WHAT THIS SUPPORTS
FOR sampling this patient now
The EXPERT-COHORT matched the urologist in 16 of 18 cases in this exact situation.
The EXPERT-CLASSIFIER suggested biopsy with a probability of 0.72.
AGAINST sampling this patient now
The EXPERT-EAU noted that the mpMRI prose does not compare against an earlier study, so the guideline does not mandate a specific action based on this point.

WHERE THIS LEANS
The data suggests a leaning towards biopsy based on the cohort matching, but the lack of comparison in the MRI prose leaves the decision unresolved.
LEAN: biopsy

## Intervención 14 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 3

SUFFICIENCY
The registrar has now answered the moderator's question Q1 by reporting that the PSA fraction is "21%" on "04 Feb 2025".

ALIGNMENT WITH THE CLASSIFIER
The retrieved evidence aligns with the EXPERT-CLASSIFIER's suggestion of biopsy because the cohort matching and classifier suggestion lean towards biopsy, which is supported by the finding that a prior biopsy was negative and the contextual information from the laboratory results.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What are the laboratory results, specifically regarding the PSA fraction, infection, or prostatitis, to contextualize the PSA value? Answered by the registrar, who stated the PSA fraction is "21%" on "04 Feb 2025".

WHAT CARRIES WEIGHT, AND WHY
The two most relevant variables are the prior biopsy result, because the negative result is a key factor in the decision pathway, and the laboratory results, because the guideline requires context regarding PSA fraction to individualize the need for biopsy. The guideline does not support the leaning towards biopsy because the lack of comparison in the mpMRI prose leaves the decision unresolved.

MY SUGGESTION TO THE CHAIR
Given that the prior biopsy was negative and the laboratory results have now provided the required context regarding the PSA fraction, the evidence strongly supports proceeding with a biopsy.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 3: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 15 — CHAIR

*the senior urologist who signs the decision* · vuelta 3

MY DECISION: BIOPSY   (confidence: clear)

Given the prior negative biopsy and the PI-RADS 4 score on the mpMRI, the cohort data strongly supports repeating the biopsy. The laboratory results provided context via the PSA fraction, which, combined with the prior negative result, made the decision clear. The evidence converged on proceeding with a repeat biopsy to confirm histological progression.

What carried weight: bx=decisive, age=important, dre=noted, psa=important, vol=noted, psad=important, cspca=noted, pirads=decisive, comorbidity=noted
Documents this conference opened: psa_trend, radiology_report, previous_notes, laboratory_results
